InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum
10 août 2021 07h30 HE
|
InflaRx N.V.
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesionTreatment was well tolerated; no adverse events associated with dose...
InflaRx to Present at the BTIG Virtual Biotechnology Conference
06 août 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will...
InflaRx Reports Second Quarter 2021 Financial & Operating Results
05 août 2021 07h30 HE
|
InflaRx N.V.
Severe COVID-19 trial enrollment reaches 299 patients; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable...
InflaRx to Present at the Raymond James Human Health Innovation Conference
17 juin 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
08 juin 2021 07h30 HE
|
InflaRx N.V.
Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumab JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage...
Tony Gibney Joins InflaRx Board of Directors
21 mai 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, May 21, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports First Quarter 2021 Financial & Operating Results
12 mai 2021 07h30 HE
|
InflaRx N.V.
Severe COVID-19 trial enrollment reaches 178 patients; interim analysis expected in Q3 At the FDA’s suggestion, planning to request a Type A meeting to further discuss primary endpoint for the Phase...
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
11 mai 2021 16h30 HE
|
InflaRx N.V.
U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of careEU IXCHANGE...
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum
15 avr. 2021 07h30 HE
|
InflaRx N.V.
Target enrollment of 18 patients reached across three different dose groupsInterim results will be available by the end of 2021 with final results expected in 2022Initial positive data from the first...
InflaRx Reports Full Year 2020 Financial & Operating Results
25 mars 2021 06h30 HE
|
InflaRx N.V.
Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021Phase III trial in Severe COVID-19 is ongoing and recruiting...